Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Thomas Jensen to Humans

This is a "connection" page, showing publications Thomas Jensen has written about Humans.

 
Connection Strength
  
 
 
0.103
  
  1. Lindsay M, Arndt G, Wieland A, Jensen T. Evolving Role of GLP-1 Therapies in Liver Disease. Curr Gastroenterol Rep. 2025 Jun 06; 27(1):36.
    View in: PubMed
    Score: 0.024
  2. Shah SJ, Sharma K, Borlaug BA, Butler J, Davies M, Kitzman DW, Petrie MC, Verma S, Patel S, Chinnakondepalli KM, Einfeldt MN, Jensen TJ, Rasmussen S, Asleh R, Ben-Gal T, Kosiborod MN. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials. Eur Heart J. 2024 Sep 14; 45(35):3254-3269.
    View in: PubMed
    Score: 0.006
  3. Verma S, Butler J, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, Shah SJ, Jensen TJ, Rasmussen S, Rönnbäck C, Merkely B, O'Keefe E, Kosiborod MN. Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program. J Am Coll Cardiol. 2024 Oct 22; 84(17):1603-1614.
    View in: PubMed
    Score: 0.006
  4. Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Verma S, Jensen TJ, Einfeldt MN, Liisberg K, Perna E, Sharma K, Ezekowitz JA, Fu M, Melenovský V, Ito H, Lelonek M, Kosiborod MN. Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program. J Am Coll Cardiol. 2024 Jul 02; 84(1):27-40.
    View in: PubMed
    Score: 0.006
  5. Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Møller DV, Treppendahl MB, Verma S, Jensen TJ, Liisberg K, Lindegaard ML, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovský V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Shah SJ. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024 04 18; 390(15):1394-1407.
    View in: PubMed
    Score: 0.006
  6. Jensen TJ, Haarbo J, Pehrson SM, Thomsen B. Impact of premature atrial contractions in atrial fibrillation. Pacing Clin Electrophysiol. 2004 Apr; 27(4):447-52.
    View in: PubMed
    Score: 0.006
  7. Kobo O, Cavender MA, Jensen TJ, Kuhlman AB, Rasmussen S, Verma S. Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis. Diabetes Obes Metab. 2024 Mar; 26(3):1129-1132.
    View in: PubMed
    Score: 0.005
  8. Kosiborod MN, Verma S, Borlaug BA, Butler J, Davies MJ, Jon Jensen T, Rasmussen S, Erlang Marstrand P, Petrie MC, Shah SJ, Ito H, Schou M, Melenovský V, Abhayaratna W, Kitzman DW. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial. Circulation. 2024 01 16; 149(3):204-216.
    View in: PubMed
    Score: 0.005
  9. Jensen TJ, Haarbo J, Pehrson SM, Thomsen PE. Paroxysmal atrial fibrillation: ectopic atrial activity and prevalence of severely symptomatic patients. Pacing Clin Electrophysiol. 2003 Aug; 26(8):1668-74.
    View in: PubMed
    Score: 0.005
  10. Andres-Hernando A, Jensen TJ, Kuwabara M, Orlicky DJ, Cicerchi C, Li N, Roncal-Jimenez CA, Garcia GE, Ishimoto T, Maclean PS, Bjornstad P, Sanchez-Lozada LG, Kanbay M, Nakagawa T, Johnson RJ, Lanaspa MA. Vasopressin mediates fructose-induced metabolic syndrome by activating the V1b receptor. JCI Insight. 2021 01 11; 6(1).
    View in: PubMed
    Score: 0.004
  11. Crowley MJ, McGuire DK, Alexopoulos AS, Jensen TJ, Rasmussen S, Saevereid HA, Verma S, Buse JB. Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. Diabetes Care. 2020 09; 43(9):e108-e110.
    View in: PubMed
    Score: 0.004
  12. Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. Diabetes Care. 2018 08; 41(8):1663-1671.
    View in: PubMed
    Score: 0.004
  13. Ahrén B, Hirsch IB, Pieber TR, Mathieu C, Gómez-Peralta F, Hansen TK, Philotheou A, Birch S, Christiansen E, Jensen TJ, Buse JB. Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Diabetes Care. 2016 Oct; 39(10):1693-701.
    View in: PubMed
    Score: 0.003
  14. Jensen TJ, Hilsted JC. [Pharmacological prevention of late complications of diabetes]. Ugeskr Laeger. 1996 Apr 22; 158(17):2402-3.
    View in: PubMed
    Score: 0.003
  15. van den Brink W, Strang J, Gual A, Sørensen P, Jensen TJ, Mann K. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. Expert Opin Drug Saf. 2015 Apr; 14(4):495-504.
    View in: PubMed
    Score: 0.003
  16. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Under-reporting of adverse effects of tesofensine. Lancet. 2013 Jul 13; 382(9887):127.
    View in: PubMed
    Score: 0.003
  17. Verhamme P, Pakola S, Jensen TJ, Berggren K, Sonesson E, Saint-Remy JM, Balchen T, Belmans A, Cahillane G, Stassen JM, Peerlinck K, Glazer S, Jacquemin M. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther. 2010 Jun; 32(6):1205-20.
    View in: PubMed
    Score: 0.002
  18. Nielsen AL, Larsen TM, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Astrup A. [The effect of tesofensine on body weight and body composition in obese subjects--secondary publication]. Ugeskr Laeger. 2009 Oct 05; 171(41):2974-7.
    View in: PubMed
    Score: 0.002
  19. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 11 29; 372(9653):1906-1913.
    View in: PubMed
    Score: 0.002
  20. Bloch Thomsen PE, Joergensen RM, Kanters JK, Jensen TJ, Haarbo J, Hagemann A, Vestergaard A, Saermark K. Phase 2 reentry in man. Heart Rhythm. 2005 Aug; 2(8):797-803.
    View in: PubMed
    Score: 0.002
  21. Hansen CN, Jensen TJ, Borch-Johnsen K. [Dyslipidemia, diabetes and cardiovascular disease]. Ugeskr Laeger. 2000 Aug 14; 162(33):4367-70.
    View in: PubMed
    Score: 0.001
  22. Deckert T, Yokoyama H, Mathiesen ER, Rønn B, Jensen TJ, Feldt-Rasmussen BF, Borch-Johnsen K, Jensen JS. [Microalbuminuria as predictor of atherosclerotic cardiovascular disease in IDDM]. Ugeskr Laeger. 1997 May 12; 159(20):3010-4.
    View in: PubMed
    Score: 0.001
  23. Skovby F, Dyerberg J, Faergeman O, Haghfelt T, Jensen TJ, Leth A, Sigurd B, Stender S, Vittrup MA. [Hyperlipidemia in children]. Ugeskr Laeger. 1993 Mar 15; 155(11):810-4.
    View in: PubMed
    Score: 0.001
  24. Dyerberg J, Stender S, Andersen GE, Faergeman O, Haghfelt T, Hviid T, Jensen TJ, Leth A, Sigurd B, Skovby F. [Recommendations for clinical-chemical departments: lipid-lipoprotein analysis]. Ugeskr Laeger. 1990 May 14; 152(20):1434-7.
    View in: PubMed
    Score: 0.001
  25. Buchanan JA, Yeger H, Tabcharani JA, Jensen TJ, Auerbach W, Hanrahan JW, Riodan JR, Buchwald M. Transformed sweat gland and nasal epithelial cell lines from control and cystic fibrosis individuals. J Cell Sci. 1990 Jan; 95 ( Pt 1):109-23.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)